Table 3.
Neurologic outcomes using the GAS scoring system in patients with Wilson’s disease during the treatment.
| Group | Baseline | 4 weeks | 6 months | 4 weeks | 1 year | |
|---|---|---|---|---|---|---|
| 1 (n = 21) | Scores | 13.4 ± 5.6 | 12.2 ± 4.7 | 11.8 ± 5.3* | 11.2 ± 5.1** | 10.7 ± 4.3** |
| Improvement (n, %) | 8 (38.1) | 12 (57.1) | 14 (66.7) | 16 (76.2) | ||
| Deterioration (n, %) | 3 (14.3) | 4 (19.0) | 4 (19.0) | 4 (19.0) | ||
| 2 (n = 17) | Scores | 14.2 ± 6.1 | 14.4 ± 6.3 | 14.9 ± 6.7 | ||
| Improvement (n, %) | 1 (5.9) | 2 (11.8) | ||||
| Deterioration (n, %) | 4 (23.5) | 5 (29.4) |
*
p < 0.05; **p < 0.01.